During the 47th Union World Conference on Lung Health in Liverpool, U.K. (October 2016), Otsuka reported it is developing OPC-167832 in combination with delamanid. OPC- 167832 is intended to target both drug-susceptible as well as drug-resistant forms of TB, and has a different mechanism of action than all currently approved anti-TB drugs. MIC for M. tuberculosis 0.00024 to 0.002 ug/ml. Mouse models of chronic TB studies showed that delamanid and OPC-167832, along with one or two other new anti-TB drugs, are more effective than standard regimens against both drug-susceptible as well as multidrugresistant TB. Early results suggest that regimens with OPC-167832 and delamanid at the core could potentially shorten treatment duration and improve treatment outcomes. The US FDA has already granted the investigation of OPC-167832 a Fast Track status, and human trials are underway.